Ticker > Company >

Sandu Pharmaceutical share price

Sandu Pharmaceuticals Ltd.

BSE: 524703 SECTOR: Pharmaceuticals & Drugs  10.86 K   22   0

44.12
-1.04 (-2.30%)
BSE: Today, 01:31 PM

Price Summary

Today's High

₹ 45

Today's Low

₹ 43.75

52 Week High

₹ 64.85

52 Week Low

₹ 43.75

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

42.62 Cr.

Enterprise Value

41.43 Cr.

No. of Shares

0.97 Cr.

P/E

26.56

P/B

1.01

Face Value

₹ 10

Div. Yield

1.81 %

Book Value (TTM)

₹  43.72

CASH

1.2 Cr.

DEBT

0 Cr.

Promoter Holding

42.9 %

EPS (TTM)

₹  1.66

Sales Growth

2.96%

ROE

3.66 %

ROCE

5.35%

Profit Growth

-4.15 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.96%
3 Year4.62%
5 Year6.36%

Profit Growth

1 Year-4.15%
3 Year10.16%
5 Year16.9%

ROE%

1 Year3.66%
3 Year4.85%
5 Year4.65%

ROCE %

1 Year5.35%
3 Year7.2%
5 Year7.05%

Debt/Equity

0

Price to Cash Flow

55.98

Interest Cover Ratio

33.8937

CFO/PAT (5 Yr. Avg.)

2.46196435723087

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 42.90 0.00
Mar 2025 42.90 0.00
Dec 2024 42.90 0.00
Sep 2024 42.90 0.00
Jun 2024 42.90 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 33.8937.
  • The company has an efficient Cash Conversion Cycle of 27.7386 days.
  • Company has a healthy liquidity position with current ratio of 2.0955.
  • The company has a good cash flow management; CFO/PAT stands at 2.46196435723087.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 7.74420390681723.

 Limitations

  • The company has shown a poor revenue growth of 4.61977832711657% for the Past 3 years.
  • Company has a poor ROE of 4.84884819143897% over the past 3 years.
  • The company has a low EBITDA margin of 3.57871440488845% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 17.05 17.71 18.37 14.07 16.7
Total Expenditure 16.64 16.79 17.38 13.62 16.18
Operating Profit 0.41 0.92 0.99 0.45 0.52
Other Income 0.05 0.03 0.03 0.07 0.02
Interest 0.02 0.03 0.03 0.03 0.03
Depreciation 0.16 0.17 0.19 0.15 0.18
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.27 0.74 0.8 0.34 0.34
Tax 0.11 0.24 0.24 0.02 0.12
Profit After Tax 0.17 0.5 0.56 0.33 0.22
Adjusted EPS (Rs) 0.17 0.52 0.57 0.34 0.23

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 48.45 58.76 65.5 65.35 67.28
Total Expenditure 46.91 56.6 62.63 62.86 64.98
Operating Profit 1.53 2.16 2.87 2.49 2.3
Other Income 0.38 0.19 0.08 0.33 0.42
Interest 0.43 0.12 0.11 0.08 0.06
Depreciation 0.55 0.56 0.53 0.52 0.58
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.92 1.68 2.32 2.22 2.07
Tax 0.2 0.59 0.73 0.7 0.61
Net Profit 0.72 1.09 1.59 1.52 1.46
Adjusted EPS (Rs.) 1.02 1.38 1.8 1.58 1.51

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 7.08 7.92 8.81 9.66 9.66
Total Reserves 22.16 25.57 27.66 29.58 30.93
Borrowings 0 0 0 0 0
Other N/C liabilities 0.85 0.95 0.94 1.04 1.18
Current liabilities 11.33 12.52 11.87 13.88 10.64
Total Liabilities 41.41 46.96 49.28 54.17 52.42
Assets
Net Block 16.6 16.17 16 16.62 17.88
Capital WIP 0 0 0.48 0.42 0
Intangible WIP 0 0 0 0 0
Investments 0.82 0.24 9.11 9.66 10.43
Loans & Advances 1.32 0 0 0 0
Other N/C Assets 0.25 0 0.05 1.94 1.82
Current Assets 22.42 30.54 23.65 25.54 22.3
Total Assets 41.41 46.96 49.28 54.17 52.42
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 0.92 1.68 2.32 2.22 2.07
Adjustment 0.96 0.62 0.63 0.48 0.41
Changes in Assets & Liabilities 4.47 5.75 -1.13 -1.78 -1.22
Tax Paid -0.14 -0.46 -0.88 -0.7 -0.5
Operating Cash Flow 6.2 7.59 0.95 0.22 0.76
Investing Cash Flow -0.37 -5.58 -5.47 0.53 -1.31
Financing Cash Flow -5.36 1.3 0.93 0.58 -0.72
Net Cash Flow 0.48 3.31 -3.59 1.33 -1.27

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 42.90 42.90 42.90 42.90 42.90
akshath finvest and prope... 5.12 5.12 5.12 5.12 5.12
geeta u sandu 0.88 0.88 0.88 0.88 0.88
jayshree bhaskar sandu 7.63 7.63 7.63 7.63 7.63
minal shashank sandu 0.63 0.63 0.63 0.63 0.63
shashank bhaskar sandu 14.17 14.17 14.17 14.17 14.17
shubhada prabhakar sandu 0.10 0.10 0.10 0.10 0.10
umesh bhaskar sandu 14.37 14.37 14.37 14.37 14.37
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 57.10 57.10 57.10 57.10 57.10
hitesh kuvelkar 1.26 1.26 1.26 1.26 1.26
llp 0.34 0.35 0.38 0.23 0.22
neelamber leasing and fin... 4.71 4.71 4.71 4.71 4.71
noumura realty and constr... 2.27 2.27 2.27 2.27 2.27
phybrichem engineers priv... 1.61 1.61 1.61 1.61 1.61
sanbro marketing services... 2.59 2.59 2.59 2.59 2.59
sanmark realty and financ... 5.63 5.63 5.63 5.63 5.63
tanvi jignesh mehta 2.41 2.54 2.42 3.29 4.54
trans scan securities pri... 1.04 - - - -
yogish shetty 1.07 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Sandu Pharmaceuticals informs about compliances-certificate 7 Oct, 5:31 PM Sandu Pharmaceuticals informs about closure of trading window 24 Sep, 11:06 AM Sandu Pharmaceutical - Quaterly Results 13 Aug, 5:56 PM Sandu Pharmaceutical - Quaterly Results 13 Aug, 5:56 PM Sandu Pharmaceuticals informs about disclosure 21 Apr, 9:53 AM Sandu Pharmaceuticals informs about clarification 19 Feb, 5:16 PM Sandu Pharmaceuticals informs about newspaper cutting 15 Feb, 2:25 PM Sandu Pharmaceutical - Quaterly Results 13 Feb, 5:33 PM Sandu Pharmaceutical - Quaterly Results 13 Feb, 5:33 PM Sandu Pharmaceuticals informs about disclosure 21 Jan, 5:22 PM Sandu Pharmaceuticals informs about certificate 9 Jan, 12:56 PM Sandu Pharmaceuticals informs about closure of trading window 21 Dec, 3:18 PM Sandu Pharmaceuticals informs about stop transfer receipt 18 Dec, 1:08 PM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 2 Dec, 4:00 PM Sandu Pharmaceuticals informs about closure of trading window 23 Sep, 12:16 PM Sandu Pharmaceuticals informs about stop transfer request 21 Sep, 10:28 AM Sandu Pharmaceuticals informs about stop transfer request 21 Aug, 3:18 PM Sandu Pharmaceutical - Quaterly Results 12 Aug, 7:36 PM Sandu Pharmaceutical - Quaterly Results 12 Aug, 7:36 PM Sandu Pharmaceuticals informs about details of loss of certificate 8 Aug, 2:29 PM Sandu Pharmaceuticals informs about board meeting 3 Aug, 2:28 PM Sandu Pharmaceuticals informs about stop transfer request 20 Jun, 1:01 PM Sandu Pharmaceutical - Quaterly Results 5 Jun, 7:22 PM Sandu Pharmaceutical - Quaterly Results 5 Jun, 7:22 PM Sandu Pharmaceuticals informs about loss of share certificate 14 May, 2:12 PM Sandu pharmaceuticals informs about details of loss of certificate 4 May, 11:24 AM Sandu Pharmaceuticals informs about stop transfer receipt 30 Apr, 12:44 PM Sandu Pharmaceuticals informs about details of loss of certificate 16 Apr, 4:58 PM Sandu Pharmaceuticals informs about compliance certificate 11 Apr, 1:36 PM Sandu Pharmaceuticals informs about stop transfer request 30 Mar, 11:10 AM Sandu Pharmaceuticals informs about details of loss of certificate 20 Mar, 1:01 PM Sandu Pharmaceuticals informs about details of loss of certificate 8 Mar, 12:24 PM Sandu Pharmaceutical - Quaterly Results 14 Feb, 9:04 PM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 20 Jan, 12:30 PM Sandu Pharmaceuticals informs about resignation of CFO 22 Nov, 5:12 PM Sandu Pharmaceuticals informs about details of loss of certificate 18 Nov, 10:59 AM Sandu Pharmaceuticals informs about stop transfer request 21 Oct, 11:06 AM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 25 Sep, 10:50 AM Sandu Pharmaceuticals informs about issuance of duplicate shares certificate 6 Sep, 12:28 PM Sandu Pharmaceuticals informs about stop transfer intimation 11 Aug, 11:55 AM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 29 Jul, 10:17 AM Sandu Pharmaceuticals informs about loss of share certificates 21 Jul, 12:15 PM Sandu Pharmaceuticals informs about loss of share certificate 15 Jul, 10:29 AM Sandu Pharmaceuticals informs about loss of share certificate 1 Jul, 12:27 PM Sandu Pharmaceuticals informs about loss of share certificate 15 Jun, 2:30 PM Sandu Pharmaceuticals informs about issuance of duplicate share certificate 9 May, 12:29 PM Sandu Pharmaceuticals informs about closure of trading window 23 Mar, 12:23 PM Sandu Pharmaceuticals informs about details of loss of certificate 18 Mar, 3:45 PM Sandu Pharmaceuticals informs about stop transfer request 14 Mar, 12:42 PM Sandu Pharmaceuticals informs about disclosure 25 Feb, 2:25 PM

Sandu Pharmaceutical Stock Price Analysis and Quick Research Report. Is Sandu Pharmaceutical an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sandu Pharmaceutical. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sandu Pharmaceutical has a PE ratio of 26.8885812315656 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sandu Pharmaceutical has ROA of 2.7408% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sandu Pharmaceutical has a Current ratio of 2.0955.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sandu Pharmaceutical has a ROE of 3.6588%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Sandu Pharmaceutical has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Sandu Pharmaceutical has reported revenue growth of 2.956% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Sandu Pharmaceutical for the current financial year is 3.41450074092569%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sandu Pharmaceutical is Rs 0.8 and the yield is 1.7909%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sandu Pharmaceutical is Rs 1.6613. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sandu Pharmaceutical in Ticker for free. Also, one can get the intrinsic value of Sandu Pharmaceutical by using Valuation Calculators, which are available with a Finology ONE subscription. 

Sandu Pharmaceutical FAQs

Q1. What is Sandu Pharmaceutical share price today?
Ans: The current share price of Sandu Pharmaceutical is Rs 44.67.

Q2. What is the market capitalisation of Sandu Pharmaceutical?
Ans: Sandu Pharmaceutical has a market capitalisation of Rs 43.15564233 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Sandu Pharmaceutical?
Ans: The PE ratio of Sandu Pharmaceutical is 26.8885812315656 and the P/B ratio of Sandu Pharmaceutical is 1.0216777746774, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Sandu Pharmaceutical share?
Ans: The 52-week high share price of Sandu Pharmaceutical is Rs 64.85, and the 52-week low share price of Sandu Pharmaceutical is Rs 43.75.

Q5. Does Sandu Pharmaceutical pay dividends?
Ans: Currently, Sandu Pharmaceutical pays dividends. Dividend yield of Sandu Pharmaceutical is around 1.7909%.

Q6. What are the face value and book value of Sandu Pharmaceutical shares?
Ans: The face value of Sandu Pharmaceutical shares is Rs 10, while the book value per share of Sandu Pharmaceutical is around Rs 43.7222. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Sandu Pharmaceutical?
Ans: Sandu Pharmaceutical has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Sandu Pharmaceutical?
Ans: The ROE of Sandu Pharmaceutical is 3.6588% and ROCE of Sandu Pharmaceutical is 5.349%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Sandu Pharmaceutical a good buy for the long term?
Ans: The Sandu Pharmaceutical long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Sandu Pharmaceutical undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Sandu Pharmaceutical appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Sandu Pharmaceutical’s financials?
Ans: You can review Sandu Pharmaceutical’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Sandu Pharmaceutical
X